inclusion criteria: to be eligible to participate in this study, a subject must meet all of the following criteria: * age of 18 years or older * life expectancy \> 12 months * ability to provide informed consent additional criteria for cohort a: • partner of a participating patient additional criteria for cohort b: * histological diagnosis of a solid malignancy * treatment with monotherapy immune checkpoint inhibitor (ici) against programmed death 1 (pd1) or its ligand pd-l1 (in curative or non-curative setting) * last ici administration within 3 months of vaccination additional criteria for cohort c: * histological diagnosis of a solid malignancy * treatment with cytotoxic chemotherapy (monotherapy and combination chemotherapy is allowed, as well as a combination with radiotherapy, in curative or non-curative setting) * last chemotherapy administration within 4 weeks of vaccination additional criteria for cohort d: * histological diagnosis of a solid malignancy * treatment with a pd1 or pd-l1 antibody in combination with cytotoxic chemotherapy (in curative or non-curative setting) * last chemotherapy administration within 4 weeks of vaccination * last ici administration within 3 months of vaccination

inclusion criteria: to be eligible to participate in this study, a subject must meet all of the following criteria: * age of 18 years or older * life expectancy \> 12 months * ability to provide informed consent additional criteria for cohort a: • partner of a participating patient additional criteria for cohort b: * histological diagnosis of a solid malignancy * treatment with monotherapy immune checkpoint inhibitor (ici) against programmed death 1 (pd1) or its ligand pd-l1 (in curative or non-curative setting) * last ici administration within 3 months of vaccination additional criteria for cohort c: * histological diagnosis of a solid malignancy * treatment with cytotoxic chemotherapy (monotherapy and combination chemotherapy is allowed, as well as a combination with radiotherapy, in curative or non-curative setting) * last chemotherapy administration within 4 weeks of vaccination additional criteria for cohort d: * histological diagnosis of a solid malignancy * treatment with a pd1 or pd-l1 antibody in combination with cytotoxic chemotherapy (in curative or non-curative setting) * last chemotherapy administration within 4 weeks of vaccination * last ici administration within 3 months of vaccination

inclusion criteria: to be eligible to participate in this study, a subject must meet all of the following criteria: - age of 18 years or older - life expectancy > 12 months - ability to provide informed consent additional criteria for cohort a: • partner of a participating patient additional criteria for cohort b: - histological diagnosis of a solid malignancy - treatment with monotherapy immune checkpoint inhibitor (ici) against programmed death 1 (pd1) or its ligand pd-l1 (in curative or non-curative setting) - last ici administration within 3 months of vaccination additional criteria for cohort c: - histological diagnosis of a solid malignancy - treatment with cytotoxic chemotherapy (monotherapy and combination chemotherapy is allowed, as well as a combination with radiotherapy, in curative or non-curative setting) - last chemotherapy administration within 4 weeks of vaccination additional criteria for cohort d: - histological diagnosis of a solid malignancy - treatment with a pd1 or pd-l1 antibody in combination with cytotoxic chemotherapy (in curative or non-curative setting) - last chemotherapy administration within 4 weeks of vaccination - last ici administration within 3 months of vaccination

inclusion criteria: to be eligible to participate in this study, a subject must meet all of the following criteria: - age of 18 years or older - life expectancy > 12 months - ability to provide informed consent additional criteria for cohort a: • partner of a participating patient additional criteria for cohort b: - histological diagnosis of a solid malignancy - treatment with monotherapy immune checkpoint inhibitor (ici) against programmed death 1 (pd1) or its ligand pd-l1 (in curative or non-curative setting) - last ici administration within 3 months of vaccination additional criteria for cohort c: - histological diagnosis of a solid malignancy - treatment with cytotoxic chemotherapy (monotherapy and combination chemotherapy is allowed, as well as a combination with radiotherapy, in curative or non-curative setting) - last chemotherapy administration within 4 weeks of vaccination additional criteria for cohort d: - histological diagnosis of a solid malignancy - treatment with a pd1 or pd-l1 antibody in combination with cytotoxic chemotherapy (in curative or non-curative setting) - last chemotherapy administration within 4 weeks of vaccination - last ici administration within 3 months of vaccination